Research involving humans has demonstrated positive outcomes, such as enhanced vascular endothelial function in chronic kidney disease patients who do not require dialysis, following a 12-week treatment with the IL-1 inhibitor rilonacept [226]. This evidence concerns the gene IL1B and chronic kidney disease.